Sign in
Taking peopleNo phase

Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients

Key facts

Who runs it
ALPS Biotech CO. LTD
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
60 people, planned
Started
16 Sept 2024
Expected to end
31 Aug 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Antrodia cinnamomea Products
Record updated
10 December 2024

Who can take part

Age
30 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adults aged 30 to 70 years, whose native language is Chinese
  • Patients diagnosed with Spinocerebellar Ataxia
  • Subjects with a score below 30 on the Scale for the Assessment and Rating of Ataxia (SARA scale)
  • Individuals who can read and write in Chinese and communicate in Chinese
  • Agree to participate in the study

Who cannot take part

  • Patients who have taken Antrodia cinnamomea products within the last 6 months prior to the trial
  • Patients with severe systemic diseases, such as heart or respiratory failure, liver or kidney failure, severe brain injury, prolonged bed rest, or incurable malignancies
  • Pregnant women and breastfeeding mothers
  • Patients with other factors that prevent them from continuing to participate in this study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 30 and 70 years old?

This trial is currently available in Taiwan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.

The 2 groups in the trial

  • Stage I: Antrodia Cinnamomea Products + Stage II: PlaceboExisting treatment, for comparison

    Crossover design: During 0 week\~8 weeks is Stage I : • Dietary Supplement: Antrodia Cinnamomea Products During 16 weeks\~ 24 weeks is Stage II: • Dietary Supplement: Placebo

    Treatment: Antrodia cinnamomea Products

  • Stage I: Placebo + Stage II: Antrodia Cinnamomea ProductsPlacebo, for comparison

    Crossover design: During 0 week\~8 weeks is Stage I : • Dietary Supplement: Placebo During 16 weeks\~ 24 weeks is Stage II: • Dietary Supplement: Antrodia Cinnamomea Products

    Treatment: Antrodia cinnamomea Products

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06633003, who can take part
Record updated
10 December 2024